Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$94 Mln
P/E Ratio
--
P/B Ratio
24.26
Industry P/E
--
Debt to Equity
-3.13
ROE
-10.51 %
ROCE
-33.21 %
Div. Yield
0 %
Book Value
--
EPS
-2.15
CFO
$-476.60 Mln
EBITDA
$-472.90 Mln
Net Profit
$-562.06 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
OptiNose (OPTN)
| 38.92 | 1.20 | 41.68 | -33.14 | -34.68 | -31.15 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
OptiNose (OPTN)
| -65.18 | -30.27 | 14.20 | -60.87 | -55.10 | 48.71 | -67.00 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,574.08 | 58.3 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,704.70 | -- | -3.24 |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. The company offers XHANCE, a therapeutic product utilizing its... proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. OptiNose, Inc.was founded in 2000 and is headquartered in Yardley, Pennsylvania. Read more
CEO & Director
Dr. Ramy A. Mahmoud M.D., M.P.H.
CEO & Director
Dr. Ramy A. Mahmoud M.D., M.P.H.
Headquarters
Yardley, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of OptiNose (OPTN) stood at $ 129 Mln as on 31-Dec-24
The share price of OptiNose (OPTN) is $9.28 (NASDAQ) as of 25-Apr-2025 16:00 EDT. OptiNose (OPTN) has given a return of -34.68% in the last 3 years.
OptiNose (OPTN) has a market capitalisation of $ 94 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of OptiNose (OPTN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the OptiNose (OPTN) and enter the required number of quantities and click on buy to purchase the shares of OptiNose (OPTN).
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. OptiNose, Inc.was founded in 2000 and is headquartered in Yardley, Pennsylvania.
The CEO & director of Dr. Ramy A. Mahmoud M.D., M.P.H.. is OptiNose (OPTN), and CFO & Sr. VP is Dr. Ramy A. Mahmoud M.D., M.P.H..
There is no promoter pledging in OptiNose (OPTN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| OptiNose (OPTN) | Ratios |
|---|---|
|
Return on equity(%)
|
33.93
|
|
Operating margin(%)
|
-1.89
|
|
Net Margin(%)
|
-27.54
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of OptiNose (OPTN) was $0 Mln.
$0.02
(
